|
Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain Clinical research trials and Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain. Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain  Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain
Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain
For Condition: brain metastases
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of radiation therapy plus temozolomide to that of radiation therapy alone in treating patients who have non-small cell lung cancer that is metastatic to the brain.
Details: OBJECTIVES: I. Compare the time to symptomatic neurologic progression, in terms of worsening in 1 or more of 6 clinical categories including headaches, focal weakness, mentation and/or communication, visual changes, coordination, and new cranial neuropathy, in patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy with or without temozolomide. II. Compare the time to progression in patients treated with these regimens. III. Compare the overall response rate and overall survival in patients treated with these regimens. IV. Compare changes in disease-related symptoms in patients treated with these regimens. V. Compare the effect of these regimens on steroid usage and seizure frequency in these patients. PROTOCOL OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to prior chemotherapy (yes vs no) and recursive partitioning analysis classification (1 vs 2). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive oral temozolomide once daily on days 1-7 and 15-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive whole brain radiotherapy once daily 5 days a week for 2 weeks beginning on day 1. Arm II: Patients receive oral placebo and radiotherapy as in arm I. Quality of life is assessed on day 1 of each course, on day 30 after the last course, and then every 8 weeks until disease progression. Patients are followed at 30 days and then every 8 weeks thereafter. PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed non-small cell lung cancer - Squamous cell carcinoma - Adenocarcinoma (including large cell carcinoma) - Non-small cell cancer not otherwise specified Brain metastases - Biopsy not required - Ineligible for surgical resection or radiosurgery Systemic disease that is not in immediate need of chemotherapy --Prior/Concurrent Therapy-- Biologic therapy: No concurrent immunotherapy or biologic therapy except growth factors Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy and recovered - No more than 1 prior chemotherapy regimen for systemic metastatic disease - No prior chemotherapy for brain metastases - No prior temozolomide - Concurrent chemotherapy (docetaxel, paclitaxel, or cisplatin) to alleviate progressing systemic disease is allowed Endocrine therapy: Concurrent dexamethasone required Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy to 15% or more of total bone marrow (2 weeks for less than 15% of bone marrow) and recovered - No prior radiotherapy to 50% or more of total bone marrow - No prior radiotherapy to the brain - Prior radiotherapy for local control or palliative therapy for a painful bony lesion allowed - Concurrent radiotherapy to painful bony lesions allowed if no more than 15% of bone marrow is irradiated Surgery: - See Disease Characteristics - Prior surgery for brain metastases allowed Other: - No other concurrent investigational drugs - Recovered from toxic effects of all prior therapies --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: More than 12 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin at least 9 g/dL Hepatic: - Bilirubin no greater than 2 times upper limit of normal (ULN) - SGOT and SGPT no greater than 2 times ULN (5 times ULN if liver metastases present) - Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases present) Renal: - BUN no greater than 1.5 times ULN - Creatinine no greater than 1.5 times ULN Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No known HIV positivity or AIDS-related illness - No active nonmalignant systemic disease - No frequent vomiting or other medical condition that would preclude oral medication intake (e.g., partial bowel obstruction) - No other prior or concurrent malignancies within the past 5 years except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LaurenAbrey, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000069201; NCI-G01-2048,SPRI-P02143,MSKCC-01133
Study Start Date: October 2001
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00030836
Other Brain Metastases Studies:
1. Carmustine Implants in Treating Patients With Brain Metastases
2. Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
3. Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
4. Radiation Therapy Followed by Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Malignant Melanoma
5. Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases
Related Studies:
Other brain metastases Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Non-Small Cell Lung Cancer That is Metastatic to the Brain
|
|
|
|
|
|
|
|
